Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q3 2017 · 10-Q
Revenue$3.36M$3.36M+35.4% vs Q3 2016 Net Income$16.23M$16.23MN/M vs Q3 2016 EPS Diluted$3.84$3.84N/M vs Q3 2016 Gross Profit$1,706,000+274.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,471,000N/M Free Cash Flowderived-$1,602,000N/M Margins · derivedGross margin50.8%+32.4 pt vs Q3 2016
Operating margin-106.1%+62.6 pt vs Q3 2016
Net margin482.8%+609.7 pt vs Q3 2016
ended Dec 31, 2016 · filed Feb 17, 2017 · 48 d after period end